Immune Tolerance Network A clinical research consortium sponsored by NIAID and JDRF

Changing the tide in the fight against Type 1 Diabetes. Your beta cells are precious. Help us learn how to save them.

Recruitment is currently closed.

Recruitment is currently closed for the T1DAL trial. Please check back again soon for updates.

T1DAL is being conducted by the Immune Tolerance Network and sponsored by the National Institute of Allergy and Infectious Diseases (NIH funded), with support from the Juvenile Diabetes Research Foundation. Alefacept (Amevive ®) is a registered trademark of Astellas Pharma US, Inc.

© 2011 Immune Tolerance Network